{"cdcTestId":"2021-0016","testcaseName":"Patient is 64 years and 8 months and has received two doses of the Pfizer Covid-19 vaccine","vaccineGroup":"COVID-19","evaluationTestType":"All Valid: Forecast Test","forecastTestType":"Recommended based on interval","assessmentDate":"2021-06-30T00:00:00","patient":{"dob":"1958-03-27T00:00:00","gender":"F"},"evaluation":{"seriesStatus":"Not complete","administeredDoses":[{"dateAdministered":"2021-06-09T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2021-06-30T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"3","earliestDate":"2021-11-30T00:00:00","recommendedDate":"2021-11-30T00:00:00","pastDueDate":"0001-01-01T00:00:00"},"doses":[{"dateAdministered":"2021-06-09T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2021-06-30T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2020-10-06T20:00:00","dateUpdated":"2022-09-27T09:54:14.438","generalDescription":"This test case describes when a patient that is 64 years of age and has been administered two doses of the Pfizer Covid-19 vaccine that a booster dose should be forecast.","changedInVersion":"4.27","reasonForChange":"v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022). \nv4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 12 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022)."}